TOR Therapeutics

mTORC1 inhibition, fixed-dose combination, neuroinflammation

modulatingsmall molecule

tortherapeutics.com·Jenkintown, Pennsylvania, United States·Founded 2015

Plate C · C-EOYZ

Projects

undisclosed

drug program · high

Maintain cognitive function in early Alzheimer's disease patients and potentially address other disorders driven by mTORC1 hyperactivation.

Oral once-daily fixed-dose combination of two mTORC1 inhibitors.

Experimental program initially focused on Alzheimer's disease.

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence